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ABSTRACT

Tapaszi, Stephen R. M.S., Purdue University, May 2015. An Investigation into Syk’s
Ability to Interact with and Regulate Protein Arginine Methyltransferase Activity. Major
Professor: Robert L. Geahlen.
Spleen Tyrosine Kinase (Syk) is a 72 kDa non-receptor protein-tyrosine kinase. It
plays an essential role in B cell development and signaling downstream of many immune
receptors. However, its expression is not limited to just B cells, as it has been shown to
play a functional role in signaling in many other hematopoietic cell types such as
thymocytes, mast cells, macrophages and natural killer cells. Its expression and roles
have expanded since its original discovery; and it has now been associated with epithelial
tissues as well as tumor progression and prognosis. A particular interest has focused on
Syk and its suggested tumor suppressor role in various epithelial-based carcinomas. Loss
of Syk expression both at the mRNA and protein level in breast cancer has been
associated with loss of cell-cell adherence and increased mobility and invasiveness.
Similar effects have been observed with overexpression of protein arginine
methyltransferase five (PRMT5) and seven (PRMT7) in breast cancer, indicating a new
potential mechanism by which Syk may regulate the ability of cancer to metastasize.
Western blot analysis has demonstrated Syk’s ability to alter the di-symmetric
methylation of proteins catalyzed by PRMT5. PRMT5 and Syk were found to reside in a
complex with one another. Further analysis by immunoprecipitation indicated that the
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formation of this Syk-PRMT5 complex was dependent on nucleolin expression. A
downstream substrate of PRMT5, SUPT5H, also displayed the ability to form a complex
with Syk. SUPT5H is a component of a large complex that regulates mature B cell class
switching. A component of this complex, LEO1, was also shown to interact with Syk
through

immunoprecipitation.

These

results

suggest

Syk

interacts

with

the

methyltransferase PRMT5 and some of its substrates. Furthermore, this study indicates
that Syk is interacting with components of a complex that regulates class switch
recombination.
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CHAPTER 1: INTRODUCTION

1.1 Syk Tyrosine Kinase
Spleen Tyrosine Kinase (Syk) is a 72 kDa protein whose signal transduction
function has been extensively studied in hematopoietic cells. Syk was originally isolated
from bovine thymus (1). However, at that time it was only known to be a 40 kDa
proteolytic fragment containing a catalytic domain (1-2). Later, antibodies generated
against this fragment recognized a 72 kDa protein (2). In 1991, the first full length Syk
cDNA was isolated from porcine spleen (3). Two years later research by the Clark lab led
to the isolation of the full-length cDNA encoding the human homologue of Syk (4).
Sequencing of the Syk cDNA revealed two tandem N-terminal Src-homology 2 (SH2)
domains separated by a linker A region. The C-terminal catalytic domain is connected to
the tandem SH2 domains via the linker B region (4). Many of Syk’s autophosphorylation
sites can be found in these linker regions (5) (Figure 1.1).
In the hematopoietic cell system, Syk plays a critical role in downstream signaling
of immune receptors (6). For instance, following activation of the B cell antigen receptor
(BCR), active lyn kinase will phosphorylate the tyrosine located on cytoplasmic tails of
Igα (CD79a) and Igβ (CD79b) within the immunoreceptor tyrosine-based activation
motif (ITAM) (7). These phosphorylated ITAMs then serve as docking sites for Syk
through its tandem SH2 domains (6). This ITAM sequence can be found on numerous
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Figure 1.1 Schematic Diagram of Syk
Syk contains two tandem SH2 domains that are separated by linker A. The kinase domain
is separated from the SH2 domain by linker B. Depicted here are six autophosphorylation
sites, among which Y130 has shown to effect ITAM binding and catalytic activity upon
phosphorylation. Y342 and Y346 have been shown to be important for Syk interaction
with its binding partners. Y317 has been linked to negative regulation of Syk BCR
signaling.
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other hematopoietic cell receptors such as the T-cell receptor (TCR), FcεRI receptors on
mast cells, and activating receptors on natural killer cells (8,9). Upon docking to the
ITAMs, Syk becomes activated where it can then autophosphorylate itself at tyrosine
130, linker A region, and tyrosines 519 and 520 of the catalytic domain (10). Syk is also
susceptible to phosphorylation by Lyn upon binding to the ITAM (10). This Lyn-based
phosphorylation can occur at tyrosines 317, 342, and 346 of Syk’s linker B region, which
are also susceptible to autophosphorylation. (10). Mutational studies of Tyr-130,
replacing it with a glutamate, which mimics tyrosine phosphorylation, has a negative
effect on Syk’s ability to interact with the ITAM while simultaneously enhancing its
catalytic activity (11). A similar mutation of tyrosines 519 and 520 of the catalytic
domain has shown autophosphorylation at these sites having no effect on the catalytic
activity in vitro, but do affect Syk’s ability to signal in B cells (6,12,13). Tyrosine 317,
whose phosphorylation is both Syk and Lyn dependent, is linked to a negative regulator
of BCR Ca2+ signaling (14). Mutation of this site to a phenylalanine, mimicking a
nonphosphorylated tyrosine, increased IP3 production and subsequent intracellular Ca2+
levels (14). Interestingly, within that same Linker B region, phosphorylation of tyrosines
342 and 346 acts as docking sites for the phospholipase C-γ (PLC-γ) SH2 domain,
inducing its activation by Syk phosphorylation and downstream signaling leading to
increased IP3 and intracellular Ca2+ levels (15,16). Multiple other proteins utilize these
docking sites, such as Vav1. Vav1 uses the phosphorylated tyrosines 342 and 346 on Syk
as a docking site for its SH2 domain, where it is then phosphorylated and activates its
catalytic ability to exchange GDP for GTP on Rac-1 (17,18).

	
   4
Syk can also be found in multiple other types of cells and tissue outside the
hematopoietic cell lines. Such is the case for fibroblasts, where Syk played a repressive
role in adipogenesis of the 3T3-L1 mouse embryonic fibroblasts (19). Syk was also
reported in neuronal cells including mouse brain cells PC12 and p19 and in many
epithelial tissues. (20). Fluck et al. reported detecting Syk expression of multiple tumor
breast tissue cell lines of epithelial origin such as SKBR and MCF-7 (21). Further
investigation of Syk expression and breast tissues have demonstrated normal expression
of Syk in human breast tissues and benign breast carcinoma tissue but undetectable levels
of both Syk mRNA and protein in highly invasive breast cancer (22).

1.2 Syk in Cancer
Various studies have reported Syk’s multifaceted role in cancer. It was found to
have a tumor promoter role in hematopoietic cancers. For example, in B-cell lymphomas,
Syk is constitutively active and is required for cell growth (23,24). Further evidence
suggesting Syk’s prosurvival role was collected from clinical trials of fostamatinib, a
selective Syk inhibitor. Patients with B-cell non-Hodgkin lymphoma and small
lymphocytic leukemia/chronic lymphocytic leukemia saw tumor cell death upon
treatment with this Syk inhibitor (25).
However, Syk has been shown to be a tumor suppressor in some epithelial-based
carcinomas. Syk’s tumor suppressor role extends to various cancers including breast,
gastric, pancreatic, cervical, and hepatocellular (22,26-29). Initial evidence of Syk’s
tumor suppressor role was determined when Coopman et al. studied its expression levels
in mammary epithelial cells (22). Their finding showed Syk was expressed in normal
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breast tissues, but was low or lost at the protein and mRNA level in breast carcinomas
(22). This was expanded upon by Yuan who observed hypermethylation at the CpG
island of the Syk promoter in 30% of breast cancer cell lines, suggesting Syk silencing
through epigenetic modification, also by the Meuller group who, with siRNA and shRNA
knockdown of Syk, showed increased growth, proliferation, motility, and invasiveness in
normal MCF10A breast epithelial cells (30,31). Similar cases were seen in gastric
carcinoma, where 21 out of 61 cases of gastric carcinoma showed SYK hypermethylation
at its promoter, with subsequent reduced Syk mRNA and protein levels (26). Further
studies utilizing ectopic expression of Syk in Syk negative metastatic breast cancer cell
line MDA-MB-435BAG demonstrated that cells not expressing Syk were able to form
invasive colonies in Matrigel, where Syk expressing cells were unable to form similar
colonies and maintained their non-invasive spherical appearance (26). Hoeller et al.
demonstrated similar results in a melanoma mouse model (32). In their study, metastatic
melanoma cell lines expressing control or exogenous Syk were injected into the tail vein
of mice. After 40 days, mice without Syk expressed up to 70 metastatic lesions in 10/12
mice (32). In contrast, mice injected with Juso-Syk cells formed less than three metastatic
lesions in 8 out of 12 mice, suggesting Syk’s role in cancer invasiveness (32).

1.3 Syk signaling in Cancer Cell Motility
The ability of a cancer cell to gain motility has been associated with metastases
and lower survival rate. Reactivation of Syk in highly metastatic breast carcinomas
reduced cell motility in vitro, suggesting Syk may play a critical role in cancer
invasiveness and progression (33). Studies utilizing MCF7 breast carcinoma cells
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expressing exogenous Syk with an enhanced green fluorescent protein tag (Syk-EGFP)
enhanced the localization of vinculin, a cytoskeletal protein associated with cell-cell and
cell-matrix junction, to cell-cell junctions promoting cell-cell adhesion (34). Cortactin,
found in E-cadherin adhesion assemblies, was also shown to be relocated to sites of cellcell contact within Syk-expressing MCF7 cells (34). Further studies demonstrated that
over-expression of Syk in highly invasive MDA-MB-231 breast cancer cells reduced
motility through inhibition of the phosphatidylinositol 3’kinase (PI3K) and subsequent
down-regulation of the nuclear factor kappa-light-chain-enhancer of activated B cells
(NFκB) transactivation (35). NFκB promotes activation of matrix metalloproteinases
through urokinase-type plasminogen (uPA) (35). This suggested that Syk expression
leads to down-regulation of the NFκB followed by reduction in uPA and cell motility
(35). Reduced expression of Syk by piceatannol, a Syk inhibitor, in MCF7 cells enhanced
the NFκB activity, uPA secretion, and cell motility (35).
Interestingly, recent studies by Singh et al. suggested an association between Syk
expression and the expression of epithelial to mesenchymal transition (EMT) markers
(36). EMT is a process in which epithelial cells lose their polarity and intercellular
adhesion (37). This is associated with loss of epithelial markers, such as E-cadherin, and
gain of mesenchymal markers, such as N-cadherin, vimentin, and a motile phenotype
(37). Singh et al. demonstrated that loss of Syk expression in multiple K-Ras dependent
carcinomas was associated with a loss of E-cadherin, indicative of EMT (36). This
finding, along with previously mentioned association between Syk and cortactin, give a
strong indication loss of Syk and a subsequent gain in cancer cells motility could be
through EMT.
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1.4 Protein Arginine Methyltransferase
There are a total of nine Protein Arginine Methyltransferases (PRMT) encoded in
the mammalian genome, all of which can catalyze the transfer of one or more methyl
groups from S-adenosylmethionine (SAM) to the terminal nitrogen atoms of the
gaunidino group of an arginine residue (38,39). The nine methyltransferases can be
classified into three distinct groups: Type 1, ω-NG, NG- asymmetric dimethylarginine
(ADMA); Type 2, ω-NG, NG-symmetric dimethyarginine (SDMA); and Type 3, ω-NGmonomethylarginine (MMA) (39) (Figure 1.2). Type I includes PRMT1, PRMT2,
PRMT3, CARM1, and PRMT8. PRMT5 and PRMT7 are the only type II and type III
protein arginine methyltransferases, respectively. PRMT9 has yet to be classified (39).
These PRMTs are associated with signal transduction, gene transcription, DNA repair,
mRNA splicing, and have been linked to carcinogenesis and metastasis (39). For the
purpose of this research, attention will be given to PRMT5 and PRMT7 and their
association with cancer metastasis.
1.4.1 PRMT5
As mentioned previously, PRMT5 is the only type II methyltransferase, indicating its
ability to catalyze the symmetric addition of two methyl groups to the two terminal
guanidino group of arginine (40). PRMT5 contains a N-terminal TIM barrel domain,
followed by a Rossman fold domain, and a catalytic C-terminal β-barrel domain (40,41)
(Figure 1.3). It exists in a homodimer, whose bulk interaction between monomers is
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Figure 1.2 Schematic of Arginine Methylation by PRMT
Methylation of the guanidino nitrogen atom of the target arginine residue by various
protein arginine methyltranferases can yield three different methyl additions:
monomethylation, symmetric dimethylation, or asymmetric dimethylation. Their
methylation function has been associated with gene transcription, DNA repair, mRNA
splicing, and cancer cell progression and metastasis. As this figure displays, PRMT7 is
the only type III PRMT, and PRMT5 is the only type II PRMT.
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dependent on the Arg-Asp salt bridge formation between the TIM barrel and the
Rossman fold (40,41). The SAM binding site can be found at the N-terminal linker region
helix α-Y and the LO loop of the Rossman fold domain, creating a secluded, solventshielded catalytic active site (40,42). The active site of PRMT5 is located on the hairpin
loop, or “double-E loop,” that links β4 of the Rossman fold domain, and the αF of the βbarrel (40). This double-E loop contains a pair of glutamates, which are conserved across
all PRMT proteins and required for catalytic activity (42). These glutamates are
potentially involved in deprotonating and activating the methyl-accepting nitrogen (42).
The histone substrate binds to a groove on the surface of the β-barrel and forms
substantial interactions between the backbone of the histone with the α-Y helix large loop
linker region that connects the TIM-barrel to the Rossman fold (41,42). Upon binding,
the arginine side-chain is then inserted into a narrow tunnel formed by Leu312, Phe327,
and Trp579 where it gains access to the active site to be methylated (41). Interestingly,
tyrosine phosphorylation at Y297, Y304, and Y307 of the linker region by an oncogenic
mutant of the Janus Kinase (JAK) impaired methyltransferase activity (42,43). Y304 and
Y307 directly interacted with the histone substrates, and this interaction is disrupted by
phosphorylation (42). Phosphorylation at Y297 alters the electrostatics and geometry of
PRMT5’s substrate binding site (42). This suggests phosphorylation as a mechanism to
regulate PRMT5 through altering structural components of the catalytic site (42).
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Figure 1.3 Schematic Diagram of PRMT5
PRMT5 is made up of three domains, the TIM barrel, Rossman fold, and the β-barrel. For
it to become catalytically active it must homodimerize. This is achieved through
interactions between the TIM Barrel of one PRMT5 molecule and Rossman fold of the
other. The SAM binding site is associated with the linker region between the TIM barrel
and Rossman fold. The substrate binding is associated with the “double-E loop” that is
found in the linker region between the Rossman fold domain and the β-barrel.
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1.4.2 PRMT5 in Cancer
Increased PRMT5 expression levels have been observed in numerous carcinoma
tissues including melanomas, breast, lung, ovarian, testicular, and prostate. Its
overexpression has been associated with poor prognosis (44-49). Moreover, findings in
prostate, testicular, and lung carcinomas suggest cellular localization of PRMT5 plays a
role in progression of the disease state (49,50). In multiple prostate cancer cell lines,
cytoplasmic PRMT5 enhanced the growth in a methyltransferase activity dependent
manner, where nuclear localization inhibited cell growth in a methyltransferase activityindependent manner (49). When PRMT5 is translocated to the cytoplasm it must form a
complex with the androgen receptor interacting protein p44 in the cytoplasm in order for
prostate cancer cell growth (49). Furthermore, Gu et al. demonstrated that PRMT5 is
required for p44 translocation out of the nucleus, suggesting its critical role in prostate
cancer cell growth (49). Similar results were also found in testicular cancer, where
PRMT5 and p44 protein levels were enhanced in the cytoplasmic fractions of testicular
tumor cells (48). Studies in both high-grade non-small-cell lung carcinoma (NSCLC) and
pulmonary NET tumors were associated with higher cytoplasmic expression of PRMT5
(48). Ibrahim et al. also demonstrated that cytoplasmic localization was associated with
E-cadherin-low, vimentin-high NSCLC cell lines (46). This suggests a potential
connection between PRMT5 and EMT driven metastasis of lung cancer (46).
Unfortunately, PRMT5’s cytoplasmic signaling and role, in regards to cancer cell growth,
have yet to be identified.
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However, nuclear expression of PRMT5 has also displayed a potential role in
cancer metastasis through the EMT process. In 2008, Hou et al. demonstrated PRMT5’s
repressor role of the epithelial marking E-cadherin upon PRMT5’s translocation to the
nucleus (51). This group showed that PRMT5 binds to the AJUBA family of LIM
proteins, a corepressor for SNAIL, and the SNAIL transcription factor where it is then
translocated into the nucleus. Once in the nucleus, SNAIL then anchors the
PRMT5/AJUBA complex to E-cadherin’s promoter region where its methyltransferase
activity is involved in transcriptional repression (51). Furthermore, the Wang group
reported enhanced nuclear expression of PRMT5 in transformed B-cell lymphomas, as
opposed to normal B cells, with its expression in the nucleus associated with PRMT5
enrichment at the promoter regions of all retinoblastoma family of tumor suppressor
genes and subsequent increased H3R8 and H3R3 symmetric dimethylation and
transcriptional repression of these genes (52).

1.4.3 PRMT7
PRMT7 is a type III protein arginine methyltransferase, which means it catalyzes
the addition of a single methyl group from SAM to a target arginine residue (39,53).
Uniquely, PRMT7 is much different than its other PRMT family members. Most PRMTs
contain a single core domain that is required to homodimerize in order to become
catalytically active (53,54). PRMT7, in contrast, has two-tandem core domains forming a
single homedimer-like arrangement that is catalytically active (53) (Figure 1.4).
Moreover, the Clarke group determined that only the N-terminal core domain is
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catalytically active, as the C-terminal binding pocket was occupied by the E loop and
motif I of the C-terminal Rossman fold, and its E loop was missing the catalytic
dependent glutamate residues (53,55). This unique single core domain catalytic activity
may explain why PRMT7 catalyzes monomethylation of arginine residues (53). PRMT7
binds SAM in a similar manner as other PRMT family proteins, with SAM interacting
between the N-terminal α-helix and Rossmann fold (42,53). However, PRMT7 arginine
binding pocket is narrower than that of other PRMT proteins (53). This potentially
inhibits the monomethlyated arginine from entering the binding pocket due to steric
hinderance further indicating a type III like catalytic activity.

1.4.4 PRMT7 in Cancer
Little is known about the role PRMT7 plays in cancer. In 2008, Verbiest et al.
demonstrated that knockdown of PRMT7 in DC-3F, DC-3F/9-OH-E resistant hamster
cells and HeLa cells sensitized them to camptothecin, a topoisomerase 1 inhibitor used in
treatment of lung, ovarian, and colon cancers (56). This study suggested that PRMT7
modulated cellular sensitivity to camtothecin downstream of the TOP1-DNA cleavage
complex, but the mechanism still needs further investigation (56). It was not until 2014
that the Jun Lu et al. presented strong evidence of the role of PRMT7 in inducing
epithelial-to-mesenchymal transition and subsequent metastasis in breast cancer (57).
This group demonstrated PRMT7 expression was missing from normal breast epithelial
MCF10A cells, compared to a higher expression of PRMT7 in highly metastatic MDAMB231, MDA-MB231HM, and MDA-MB-435 breast epithelial cells (57). Moreover,
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1.4 Schematic Diagram of PRMT7
Similar to the rest of the PRMT family, PRMT7 has a core domain made up of the
Rossman fold and β-barrel. However, PRMT7 is unique in that contains two tandem core
components, and does not require dimerization to be catalytically active. Interestingly,
the N-terminal core, seen in dark purple and blue, is catalytically active, as opposed to the
C-terminal core, light purple and blue, which is catalytically inactive.
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they also showed that PRMT7 expression was enhanced in estrogen receptor negative
-

(ER ) breast carcinomas, as well as high-grade (II/III) breast carcinomas (57). Ectopic
expression of PRMT7 in MCF10A cells displayed morphologic changes in which they
lost their epithelial cell-to-cell adhesions, becoming more fibroblast like (57). This was
partnered with a loss of E-cadherin and an increase in the mesenchymal markers Ncadherin, vimetin, and fibronectin, both at the mRNA and protein levels (57). Also, these
PRMT7-MCF10A cells showed more mobility and invasive ability than empty vector
transfected MCF10A cells (57). Conversely, MDA-MB-231 cells with siRNA
knockdown of PRMT7 showed an overall increase in E-cadherin and decrease in
vimentin and fibronectin expression at the mRNA and protein levels (57). Unfortunately,
the mechanism by which PRMT7 alters the expression of E-cadherin is not fully
understood. Increased PRMT7 expression has been associated with symmetric
dimethylation of the histone 4 argine 3 (H4R2me2s). However, given the unique structure
of PRMT7 and its ability to only monomethylate arginine residues, there is still a lack of
information demonstrating how it is inducing dimethylation (40,42,57).

1.5 SUPT5H
PRMT5 targets multiple nuclear and cytoplasmic proteins for methylation.
Among these proteins is SUPT5H (spt5), a 121 kDa protein associated with the
regulation of transcription elongation (58). SUPT5H, along with a second protein,
SUPT4H (spt4), were originally isolated from S. Cerevisiae (59). Later, it was reported
that SUPT5H and SUPT4H were actually in a complex together and that their association
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was necessary for transcriptional regulation (59). This was further validated by the
Handa group through the isolation of a complex containing SUPT5H and SUPT4H from
HeLa cells that caused RNA polymerase II pausing upon treatment with the transcription
inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRG) (60). They identified
this transcription elongation complex as DRB sensitivity-inducing factor (DSIF) (60).
The Handa group went on to demonstrate that SUPT5H was required for the binding of
both SUPT5H and RNA polymerase II (61).

In support of the role SUPT5H and

SUPT4H as negative regulators of transcription elongation, Yamaguchi et al.
demonstrated by immunoprecipitation that the negative elongation factor (NELF) was
associating with the DSIF/RNA polymerase II complex and pausing RNA polymerase II
(62).
However, the opposite may be true as well. Recent findings suggest that the DSIF
complex may also play a promoter role in transcription elongation (62,63). These
findings showed that phosphorylation by the P-TEFb protein kinase of the C-terminal
domain (CTD) of RNA polymerase II and the C-terminal region (CTR) of SUPT5H led
to the dissociation of NELF, which serves as a switch from a negative to a positive
transcription role for DISF (64). Interestingly, the catalytic symmetric dimethylation of
one or more arginine residues on SUPT5H demonstrated a potential regulatory role in
altering the ability of SUPTH5 to either inhibit or promote transcription elongation by
PRMT5 (65). Studies by Kwaka and colleagues indicated that symmetric dimethylation
of SUPT5H occurred at arginine 698 and was associated with a decrease in the SUPTH5SUPT4H-RNA polymerase II interaction (65).
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SUPT5H has been associated with class switch recombination in mature B cells
(66). Class switching is the ability of a mature B cell to change its isotype by altering its
heavy chain constant region (67). This allows the B cell to switch from expressing IgM to
IgG, IgA or IgE (68). However, the complete mechanism by which class switching
occurs is still unknown. Recent findings demonstrated that class switching is induced by
B cell specific activation induced cytidine deaminase (AID) (69). However, AID does not
facilitate class switching alone and has been associated with SUPT5H at sites of RNA
polymerase II stalling at switch regions of the Ig locus (66). Consistent with these
findings, knockdown studies of SUPT5H displayed significant decreases in the ability of
cells to undergo CSR (68). Interestingly, SUPT5H is not the only protein to form a
complex with AID. The Petersen-Mahrt group was able to show that AID and SUPT5H
were also associated with the RNA polymerase-associated factor (PAF; PAF1, LEO1,
CTR9) complex, SUPT6H, and the facilitates chromatin transcription (FACT; SSPR1,
SUPT16H) complex, providing further insight into the CSR process (68).

1.6 Perspective
Syk depletion in numerous carcinoma models has been correlated with increases
in motility and invasiveness of cancer cells. However, Syk’s downstream signaling role
in cancer motility has yet to be completely understood. Recent findings have shown Syk
interaction with multiple cell-cell junction mediating proteins, with loss of these tight
junctions associated with loss of Syk. Moreover, loss of Syk has been associated with the
reduction of E-cadherin, a predominant marker of EMT. These findings demonstrate a
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potential mechanism for Syk and cancer cell invasiveness via regulation of the EMT
process. Syk, PRMT5 and PRMT7 have shown potential roles in breast cancer metastasis
through the EMT process. This correlation has driven me to investigate Syk’s potential
interaction with PRMT5 and PRMT7 and the role it plays in regulating arginine
methylation in breast cancer cells.
In a preliminary study, I was able to show that Syk expression altered disymmetric arginine methylation in MDA-MB231, MCF7, and DG75 cells through
western blot analysis. This lead to the hypothesis that Syk plays a role in PRMT family,
specifically PRMT5, methylation activity. Furthermore, in our phosphoproteomics
studies, PRMT7 was found to be potentially phosphorylated by Syk on Y24 or Y26.
These tyrosines are conserved across all PRMT family proteins, however PRMT7 is the
only methyltransferase with acidic amino acids surrounding the tyrosine. They are also
located in a region crucial for SAM binding. These findings further enhanced my
curiosity to investigate Syk’s potential regulatory role in PRMT methyltransferase
activity.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Plasmids and DNA constructs
The Syk-EGFP constructs were created by a former laboratory member as
described previously (70). The GFP-PRMT7 plasmid for mammalian expression was
provided by Dr. Steven Clarke (University of California, Los Angeles).

2.2 Cell Culture
MDA-MB-231 cells were purchased from American Type Culture Collection
(ATCC). Syk-deficient MCF7 cells were purchased from BD Biosciences. MDA-MB231 and MCF7 cells with tetracycline-regulated Syk-EGFP expression were constructed
using the T-Rex system (Invitrogen) as described previously (71). These cells were
treated with 1 µg/ml tetracycline to induce Syk-EGFP expression. Nucleolin knockdown
MDA-MD-231 cells were generated by stably infecting cells with shRNA specific for
nucleolin as described previously (72). These cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Sigma Aldrich) containing 7.5% fetal bovine serum (FBS,
Gibco), 100 IU/ml penicillin G (Sigma-Aldrich), and 100 µg/ml streptomycin (SigmaAldrich).
DG75 human B-lymphoma cells were purchased from ATCC. These cells were
grown in Roswell Park Memorial Institute medium (RPMI 1640, Sigma-Aldrich)
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containing 10% FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 50 µM 2mercaptoethanol (Sigma-Aldrich), and 1 mM sodium pyruvate (Gibco). A stable Syk
knockdown DG75 cell line was generated by infecting DG75 cells with a lentivirus
expressing the shRNA sequence for Syk as described previously (64). These cells were
isolated by puromycin selection at 1 µg/ml. DG75 cells were transiently transfected with
GFP-PRMT7 through electroporation using the GenePulser (BioRad). 1 x 107 cells were
harvested in log phase growth and resuspended in 500 µl RPMI 1640 medium. Cells were
added to an electroporation cuvette followed by the addition of 20 µg of GFP-PRMT7
plasmid and allowed to incubate for 5 min at room temperature. The cells were then
electroporated under the following parameters: voltage, 250 V; capacitance, 975 µF;
resistance, ∞ resistance; cuvette, 4 mm. Cells were then added to 10 ml of RPMI medium
and allowed to recover for 48 h.

2.3 Antibodies and Reagents
Antibodies against Syk were from Santa Cruz. Anti-nucleolin, anti-PRMT5, antiPRMT7 were purchased from Abcam, and anti-symmetric dimethylarginine was from
Millipore. Antibodies against green fluorescent protein (anti-GFP) was from Santa Cruz
and anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GPDH) was from Ambion.
Antibodies against SUPT5H and LEO1 were from Abcam and anti-phosphotyrosine (pY)
was purchased from Millipore.
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2.4 Western Blotting
Cells were washed with PBS and lysed in a buffer containing 1% NP40, 10%
glycerol, 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 10 µg/ml of both aprotinin and leupeptin, and 1 mM sodium orthovanadate
(Na3VO4). Lysates were sheared via brief sonication and centrifuged at 18,000 X g for 10
min to remove cell debris. Protein concentrations were measured using the BCA assay
(Thermo Scientific). Samples were mixed at a 1:1 ratio with a protein solubilizing
mixture containing 2.5% SDS, 2.5 mM ethylenediaminetetraacetic acid (EDTA), 25 mM
Tris/HCl, pH 8.0, pyroninY, 25% sucrose and 20% 2-mercaptoethanol. The mixture was
boiled for 10 min before loading on sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel. Samples were transferred from gel to polyvinylidene
difluoride (PVDF) membrane utilizing a Biorad transfer apparatus in a transfer buffer
containing 25 mM Tris-HCl, pH 8.3, 192 mM glycine, 20% methanol, and distilled water
for 1 h at 1 amp. Membranes were blocked in a 1% NP-40/Tris-buffered saline (TBS) and
5% goat serum and primary antibodies for one h or longer at 4° C. After incubation with
the primary antibody, membranes were washed twice with 0.05% NP-40/TBS buffer for
10 min and once with 0.5 M NaCl in TBS for 10 min. Membranes were then either
incubated with goat anti-rabbit or anti-mouse horseradish peroxidase conjugated
secondary antibodies at a dilution of 1:5000 or 1:2000, respectively, in 0.05% NP40/TBS buffer with 5% goat serum for 1 h. The membranes were washed following the
same methods as described above. Enzyme-linked chemiluminescence (ECL) reagents
(PerkinElmer) and X-ray film were utilized to detect the protein bands. The dilutions for
the primary antibodies used were: Syk 1:5000, GAPDH 1:2000, symmetric
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dimethylarginine 1:1000, PRMT5 1:1000, PRMT7 1:1000, phosphotyrosine 1:10000,
SUPT5H 1:1000, and LEO1 1:1000.

2.5 Immunoprecipitation Assays
Cells were washed with PBS and lysed in a buffer containing 1% NP40, 10%
glycerol, 50 mM Tris/HCl, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF),
10 µg/ml of both aprotinin and leupeptin, and 1 mM sodium orthovanadate (Na3VO4).
Lysates were sheared via brief sonication and centrifuged at 18,000 X g for 10 min to
remove cell debris. Protein concentrations were measured using the BCA assay. Equal
amounts of lysates were pre-cleared through the addition of either protein A-Sepharose or
protein G-Sepharose (Santa Cruz) on a rotator at 4° C for 30 min. Either protein ASepharose or protein G-Sepharose was conjugated with primary antibody for 1 h. The
pre-cleared lysates were then incubated with the beads conjugated with primary antibody
at 4° for 4 h. The protein bead mixture was washed 3 times with lysis buffer, followed by
1 wash with 250 mM NaCl. Samples were mixed with protein solubilizing mixture and
boiled 10 min before being loaded onto SDS-PAGE gel for separation. The
immuncomplexes containing bound proteins were visualized by western blotting.
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CHAPTER 3: RESULTS

3.1 Introduction
Syk has been studied extensively in hematopoietic cells, where it serves as a
downstream signaling component of the immunoreceptor tyrosine-based activation motif
(6,7,8,9). However, our understanding of its role outside of the hematopoietic system,
especially its role in tumor progression, is still in its infancy. For multiple carcinomas
such as breast, prostate, and cervical, Syk expression has been associated with a tumor
suppressor role (22,26-29) where loss of Syk is associated with enhanced cancer
proliferation, motility, and invasiveness (22,30-31).
Through mass spectrometry analyses, we were able to identify multiple substrates
that are phosphorylated in a Syk-dependent manner (73). One such protein was a
methyltransferase enzyme, PRMT7, which belongs to a family of protein arginine
methyltransferase enzymes (38,39). Interestingly, recent studies of both PRMT7 and its
family member PRMT5 have demonstrated that they are overexpressed in carcinoma
tissue such as breast cancer, and their overexpression and subsequent catalytic activity
has been linked to the increased motility and invasiveness of these tumor cells (4449,51,56,57). These observations have led to the investigation of the potential role of Syk
in the regulation of PRMT5 and PRMT7 methylation activity in cancer cell models.
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3.2 Syk Alters Di-Symmetric Arginine Methylation
I first wanted to determine if Syk could alter di-symmetric arginine methylation.
Utilizing MDA-MB-231 cells, which are Syk deficient, and a line of tetracyclineresponsive MDA-MB-231 cells that inducibly express Syk-EGFP, I performed a western
blot analysis to observe any potential change in arginine di-symmetric methylation. I
treated the Tet-responsive Syk-EGFP cells with tetracycline for 48 hours before lysing.
Cells were lysed with buffer containing 1% NP-40 and a protease inhibitor cocktail.
Proteins were separated by SDS-PAGE and transferred to a PVDF membrane. Disymmetric methylation was probed using polyclonal antibodies against di-symmetrically
methylated arginine. Syk-EGFP expression was verified using antibodies against Syk;
antibodies against GAPDH were used as a measure of equal loading. The western blot
revealed a protein of 75 kDa whose methylation was increased in the Syk-EGFPexpressing cells as compared to cells lacking Syk (Figure 3.1A).
To determine if this Syk-dependent change was specific only to MDA-MB-231
cells or could be observed in other cell types, I performed a similar experiment using a
line of MCF7 breast cancer cells that lack Syk expression as compared to a Tetresponsive line of MCF7 cells in which the expression of Syk-EGFP could be induced.
Again, a band of approximately 75 kDa was preferentially observed in the lysates of SykEGFP-expressing cells (Figure 3.1B). To determine if the methylation could also be
altered by the expression of Syk at normal endogenous levels, I compared human DG75
B lymphoma cells, which normally express Syk with a line of DG75 cells in which the
expression of Syk was reduced by expression of an shRNA directed against the Syk
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message. Again, the 75 kDa dimethylated protein was observed preferentially in the cells
expressing the higher levels of Syk (Figure 3.1C).

3.3 Interaction Between Syk and PRMT5
PRMT5 is the only arginine methyltransferase that catalyzes the symmetric
dimethylation of the terminal nitrogen atom of the guanidino group of arginine (38,39).
A previous mass spectrometric analysis of Syk-dependent substrates identified CLNS1A
a component of a methylosome complex that contains PRMT5 (74,75). This suggested
that Syk interacts with CLNS1A and, potentially, PRMT5. To determine if Syk could
associate with PRMT5, I used Syk deficient MDA-MB-231 and Tet responsive SykEGFP-expressing MDA-MB-231 cells for co-immunoprecipitation assays. Cells were
treated for 48 hour to induce the expression of Syk-EGFP. Both the Syk-deficient and
Syk-EGFP-expressing

MDA-MB-231

cells

were

lysed.

Syk-EGFP

was

immunoprecipitated utilizing GFP-nanotrap beads, which bind tightly to the EGFP tag.
Cell lystates and the immune complexes were separated by SDS-PAGE and analyzed by
western blotting using antibodies against Syk and PRMT5. Interestingly, the western blot
analysis showed that PRMT5 was indeed present in the Syk-EGFP immune complex,
confirming that Syk and PRMT5 do, in fact, associate with one another (Figure 3.2).

3.4 Nucleolin Dependent Syk-PRMT5 Interaction
In 2007, the Bates group examined proteins associated with nucleolin (76).
Nucleolin is a multifunctional protein that is involved in transcription regulation, cell
growth and proliferation (77-80). Through immunoprecipitation and mass spectrometry
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analysis, the Bates group demonstrated that PRMT5 interacts with nucleolin (76). This
was further verified by studies performed by the Grimmler group who showed that
PRMT5 was recruited to nucleolin via RioK1 (81). Recent research in our laboratory has
demonstrated that Syk also interacts with nucleolin (72). Based on these findings, I
decided to determine if nucleolin played a functional role in the PRMT5-Syk interaction.
Syk deficient MDA-MB-231, Tet-responsive Syk-EGFP-expressing MDA-MB-231, and
Tet-responsive Syk-EGFP-expressing MDA-MB-231 cells expressing shRNA for
nucleolin were induced with tetracycline to express Syk-EGFP. Syk-EGFP-MDA-MB231 cells containing the shRNA sequence for nucleolin were selected with puromycin
treatment. After 48 hours of tetracycline treatment, cells were lysed and Syk-EGFP was
immunoprecipitated with GFP-nanotrap beads. Whole cell lystates and immune
complexes were separated by SDS-PAGE and proteins were visualized by western blot
analysis using antibodies against Syk, nucleolin, PRMT5 and GAPDH. An analysis of
proteins present in the resulting immune complex confirmed a nucleolin-dependent
interaction between Syk and PRMT5, with knockdown of nucleolin associated with a
decrease in the presence of PRMT5 in the immune complex (Figure 3.3).

3.5 Syk’s Interaction with PRMT5’s Substrate SUPT5H
Since my experiments suggested that Syk was present in a complex that contained
PRMT5, I examined these complexes for the presence of other potential Syk and PRMT5
substrates. Previous work in our lab, in collaboration with the Tao lab, identified via a
mass spectrometry-based phosphoproteomic screen a large library of proteins that are
potentially phosphorylated in a Syk-dependent manner (73). Comparing the database
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Figure 3.1: Symmetric Arginine Dimethylation is Altered in a Syk-Dependent Manner in
MDA-MB-231, MCF7 and DG75 cells
Western blot anaylsis utilizing antibodies against symmetric arginine dimethylation was
performed on (A) MDA-MB-231 cells lacking or induced to express Syk-EGFP lysates,
(B) MCF7 lysates lacking or inducing expression of Syk-EGFP, (C) DG75 and Syk
shRNA knockdown DG75 cells lysates.
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Figure 3.2: Interaction Between Syk and PRMT5
Syk-EGFP was immunoprecipitated utilizing GFP-nanotrap beads from lysates of MDAMB-231 cells either lacking or expressing Syk-EGFP. The lysates and immune
complexes were separated by SDS-PAGE and analyzed by western blot using antibodies
against PRMT5 and Syk. GAPDH was used as a loading control.
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Figure 3.3: Nucleolin-Dependent Interaction Between PRMT5 and Syk
MDA-MB-231 and MDA-MB-231 cells in which nucleolin levels were knocked down
with shRNA were treated with tetracycline to induce EGFP-Syk expression and lysed 48
hours after treatment. Syk-EGFP was immunoprecipitated from cell lysates by GFPnanotrap beads. Whole cell lystates and immune complexes were separated by SDSPAGE and probed by western blot using antibodies against Syk, PRMT5, and nucleolin.
GAPDH was used as a loading control.
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with current literature, I was able to identify the SUPT5H transcription elongation factor
as both a target of PRMT5 methylation and Syk phosphorylation (65). SUPT5H is a
component of the DRB-sensitivity-inducing factor. Upon phosphorylation or methylation,
SUPT5H stimulates or inhibits transcriptional elongation respectively (63,65,82).
Utilizing Syk-deficient MDA-MB-231 and MCF7 cells, along with Tet-responsive SykEGFP-expressing MB-MDA-231 and Syk-EGFP-expressing MCF7 cells, I investigated
Syk’s potential to interact with SUPT5H. SUPT5H was immunoprecipitated using
antibodies against SUPT5H from lysates of cells lacking Syk and cells expressing the
EGFP tagged Syk after treating cells with 5 mM H2O2 for 10 minutes (conditions that
lead to the activation of Syk). Whole cell lysates and immune complexes were separated
by SDS-PAGE and probed for SUPT5H, Syk, and GAPDH via western blot analysis. Syk
appeared in the SUPT5H immune complex in both MB-MDA-231 and MCF7 cells
expressing Syk-EGFP, suggesting an interaction between Syk and SUPT5H (Figure 3.4
A, B). To determine if Syk was phosphorylating SUPT5H, I stripped and re-probed the
western blot of MCF7 cells lacking or expressing EGFP-Syk with or without H2O2
treatment with antibodies against phosphotyrosine. The western blot analysis suggested
that SUPT5H phosphorylation was enhanced with cells expressing EGFP-Syk (Figure 3.4
B).
I also wanted to examine the potential effects Syk expression might have on the
interaction between PRMT5 and SUPT5H. MDA-MB-231 cells deficient in Syk
expression or treated with tetracycline to induce Syk-EGFP were lysed and used in an
immunoprecipitation assay using antibodies against SUPT5H. The immune complex was
separated by SDS-PAGE and proteins were visualized using western blot with antibodies
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against Syk, PRMT5 and SUPT5H. PRMT5 was found in both immune complexes from
cells lacking Syk or expressing Syk-EGFP (Figure 3.5). Thus, Syk is not required for the
interaction between PRMT5 and SUPT5H.

3.6 Interaction between Syk and LEO1
Recent findings have shown that SUPT5H associates with the activation induced
cytidine deaminase and RNA polymerase-associated factor 1 complexes where it plays a
role in class switch recombination in mature B cells (68). Interestingly, we found that a
component of the PAF1 complex, LEO1, also was a protein in our library of substrates
phosphorylated in a Syk-dependent manner (73, 83). To validate a Syk interaction with
LEO1, I immunoprecipitated Syk-EGFP with GFP-nanotrap beads or LEO1 with beads
conjugated with antibodies against LEO1 from lysates of Syk deficient MDA-MB-231
and Syk-expressing MDA-MB-231 cells. The lysates and immune complexes were
separated by SDS-PAGE and analyzed by western blotting with antibodies against Syk or
LEO1.

LEO1

was

coimmunprecipitated

with

Syk-EGFP

and

Syk-EGFP

coimmunoprecipitated with LEO1, confirming an association between the two proteins
(Figure 3.6 A, B).

3.7 Syk is Part of the SUPT5H, LEO1 Complex but is not Required for its Formation
To determine if SUPT5H and LEO1 were interacting with each other in a Syk-dependent
manner, I treated MDA-MB-231 cells lacking or expressing Syk-EGFP with or without
hydrogen peroxide to activate Syk. Then, I immunoprecipitated either SUPT5H or LEO1
using antibodies against these proteins.
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Figure 3.4: Syk Interacts with SUPT5H in MDA-MB-231 and MCF7 Cells
(A) Syk deficient and tetracycline induced Syk-EGFP-expressing MDA-MB-231 cells
were lysed in 1% NP-40 lysis buffer. Cell lysates were subject to immunoprecipitation
using antibodies against SUPT5H. Lysates and immune complexes were separated by
SDS-PAGE and analyzed by western blot with antibodies against Syk and SUPT5H.
GAPDH was used as a loading control. A mock IP (m) with beads not conjugated to an
antibody were used as a control for non-specific binding. Cells were treated with 5 mM
H2O2 for 10 minutes where indicated. (B) SUPT5H was immunoprecipitated from lysates
of MCF7 cells lacking Syk or induced to express Syk-EGFP using antibodies against
SUPT5H. The lysates and the immune complexes were analyzed by western blot utilizing
antibodies against Syk, SUPT5H and phosphotyrosine. Cells were treated with 5 mM
H2O2 for 10 minutes where indicated. The migration position of Syk is indicated by the
white arrows.
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Figure 3.5: PRMT5 Interacts with SUPT5H Independent of Syk Expression
SUPT5H was immunoprecipitated from lysates of MDA-MB-231 cells lacking Syk or
expressing Syk-EGFP using antibodies against SUPT5H. The immune complex was
separated by SDS-PAGE and proteins were visualized by western blot utilizing
antibodies against SUT5H, Syk and PRMT5. A mock IP (m) with beads not conjugated
to a primary antibody was used as a control for nonspecific binding.
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Figure 3.6: Syk Interacts with LEO1 in MDA-MB-231 Cells
(A) MDA-MB-231 cells lacking Syk or expressing Syk-EGFP were lysed. Syk-EGFP
was immunoprecipitated from the cell lysate using GFP-nanotrap beads. The immune
complexes and lysates were separated on SDS-PAGE and analyzed by western blot with
antibodies against LEO1, Syk, and GAPDH. (B) Syk deficient MDA-MB-231 cells
MDA-MB-231 cells induced to express Syk-EGFP with tetracycline were lysed. LEO1
was immunoprecipitated from the lysates using antibodies against LEO1. Lysates and the
immune complexes were separated by SDS-PAGE and proteins were visualized by
western blot analysis using antibodies against LEO1, Syk and GAPDH. A mock IP (m)
was used as a control for nonspecific binding.
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Cell lysates and immune complexes were separated by SDS-PAGE and western blots
were analyzed for SUPT5H, LEO1, and Syk. GAPDH was used as a loading control.
Indeed, both SUPT5H and LEO1 associated with each other in either MDA-MB-231cells
lacking or expressing Syk-EGFP. This indicates that their association is independent of
Syk and its ability to phosphorylate SUPT5H. Syk was still coimmunoprecipitated in
both assays, suggesting it may still play a functional role within this complex (Figure
3.7).

3.8 PRMT7 is not Phosphorylated by Syk in DG75 Cells
As previously mentioned, our phosphoproteomic mass spectrometry analysis
demonstrated the potential phosphorylation of PRMT7 on tyrosines 24 and 26 (73). What
is unique about these tyrosines is the fact that they are conserved across all of the PRMT
proteins. However, PRMT7 is the only methyltransferase in the group whose tyrosines
are located in a region surrounded by acidic residues, EEDEHYDY. This is interesting as
Syk preferentially targets tyrosines in acidic regions for phosphorylation (84). Moreover,
Y24 and Y26 are located within the N-terminal region where SAM binding occurs. In an
attempt to confirm Syk’s ability to interact with and phosphorylate PRMT7, I used DG75
cells and DG75 cells where Syk levels were reduced by shRNA expression. Both cell
types were transiently transfected with PRMT7-GFP. 48 hours after transfection, cells
were lysed in 1% NP40 lysis buffer and PRMT7-GFP was immunoprecipitated from cell
lysates by incubating lysates with GFP-Trap beads. The immuncomplexes were analyzed
by western blotting using antibodies against GFP, Syk and phosphotyrosine. Western
blotting with antibodies against GFP confirmed transfection. However, neither Syk nor
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phosphotyrosine appeared in the immune complex suggesting that PRMT7 is not a target
for Syk-catalyzed phosphorylation in DG75 cells (Figure 3.8). This also suggests that Syk
may only be interacting with one methyltransferase, which is PRMT5.
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Figure 3.7: Interaction Between SUPT5H and LEO1 is Independent of Syk Expression
(A) MDA-MB-231 cells lacking or expressing Syk-EGFP were treated with 5 mM H2O2
for 10 minutes and then lysed in 1% NP-40 lysis buffer. SUPT5H was
immunoprecipitated from cell lysates using antibodies against SUPT5H conjugated to
protein A Sepharose beads. Lysates and immune complexes were separated by SDSPAGE and analyzed by western blot using antibodies against SUPT4H, LEO1 and Syk.
GAPDH was used as a loading control. A mock IP (m) was used as a control for
nonspecific binding. (B) Syk deficient or tetracycline induced Syk-EGFP expressing
MDA-MB-231 cells were lysed and LEO1 was immunoprecipitated from whole cell
lysates. Lysates and immune complexes were separated by SDS-PAGE and proteins were
visualized by western blot utilizing antibodies against LEO1, SUPT5H, Syk and
GAPDH. The migration position of Syk is indicated by the white arrows.
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Figure 3.8: Syk does not Interact with PRMT7-GFP
DG75 and DG75 Syk shRNA knockdown cells were transiently transfected with a
PRMT7-GFP vector. 48 hours after transfection, cells were treated with 5 mM H2O2 and
then lysed in buffer containing 1% NP-40. GFP-nanotrap beads were used to
immunoprecipitate GFP tagged PRMT7 from cell lysates. Lysates and immune
complexes were separated by SDS-PAGE and probed for protein expression through
western blotting using antibodies against GFP, Syk, phosphotyrosine, and GAPDH.
DG75 and DG75 Syk knockdown cells not transfected with vector were used as a
negative control.

	
   39

CHAPTER 4: DISCUSSION

4.1 Introduction
Syk kinase expression extends across a multitude of cell types. It has been
extensively studied in hematopoietic cells where it plays a critical role in downstream
signaling of immune receptors. This downstream signaling is essential for cell processes
such as B-cell activation and development (85-87). Moreover, in hematopoietic cancers
such as B-cell acute lymphocyte leukemia, non-Hodgkins lymphoma and small
lymphocytic leukemia/chronic lymphocytic leukemia, Syk expression and signaling are
associated with a tumor promoter role (23-25). This is thought to be due to tonic
signaling from the B cell receptor for antigen (88). However, the function of Syk when
expressed outside of hematopoietic tissues requires further investigation. Recent findings
demonstrate that Syk expression is associated with a tumor suppressor role in some
epithelial-based carcinomas such as breast, gastric, cervical, and hepatocellular (22,2629). In particular, loss of Syk expression both at the mRNA and protein level via
hypermethylation of its promoter is associated with poor prognosis and increased
invasiveness of breast and gastric cancers (22,26,30,31).
Investigations into the mechanisms by which loss of Syk in these epithelial-based
carcinomas leads to their increased metastatic characteristics have suggested a role in for
the kinase in epithelial-to-mesenchymal transition, a process by which cells lose polarity
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and cell-cell adhesions (36). This mechanism is supported by recent findings that Syk
associates with multiple cytoskeletal proteins that promote cell-cell adhesion (34).
Furthermore, the knockdown of Syk expression in breast cancer cells is associated with a
loss of E-cadherin, a significant marker of EMT (37). this was also true for the K-Rasaddicted pancreatic carcinomas (36). The association of Syk with this cellular mechanism
provides an interesting area of investigation, as the cellular signaling associated with Syk
and its connection with EMT has yet to be fully explored.
This led to our investigation of Syk and its signaling in cancer cell models. My
focus in this study was to examine Syk’s role in regulating symmetric arginine dimethylation, as well as exploring Syk’s ability to interact with the methyltransferase
enzymes PRMT5, which catalyzes symmetric dimethylation, and PRMT7, which
catalyzes monomethylation. The vested interest in these methyltransferase enzymes stems
from the observations that their overexpression in multiple cancer models is associated
with a loss of E-cadherin and enhanced vimentin and N-cadherin expression, which are
all known EMT markers (44-49,51,57).

4.2 Syk Alters Symmetric Dimethylation of Arginine and Interacts With PRMT5
Our preliminary studies indicated that Syk expression in DG75, MCF7, and
MDA-MB-231 cells is associated with an increase in the symmetric dimethylation of a 75
kDa protein (Figure 3.1). Previous investigations of methyltransferases demonstrated that
only PRMT5 of the PRMT family of proteins is able to catalyze the symmetric addition
of two methyl groups onto the terminal nitrogen atom of the guanidino group of arginine
(38,39). My studies demonstrate that Syk and PRMT5 interact with one another,
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providing some rationale as to how Syk expression might be regulating symmetric
dimethylation of a 75 kDa protein (Figure 3.2).
My results also demonstrated that, in MDA-MB-231 cells, the interaction between
Syk and PRMT5 is dependent on nucleolin. This is in agreement with our prior report
demonstrating Syk’s interaction with nucleolin (72) and other reports of PRMT5’s
interaction with and methylation of nucleolin (76,81). Our findings are interesting as the
interaction between PRMT5 and nucleolin is associated with changes in cellular
localization of the complex. Moreover, the cellular localization of PRMT5 plays a role in
tumor progression and prognosis (49). Teng et al. demonstrated a nucleolin mediated
nuclear-to-cytoplasmic redistribution of PRMT5 upon treatment with the oligonucleotide
aptamer AS1411, a ligand for nucleolin (76). The Grimmler group followed this
discovery with findings that suggested that RioK1, an exclusively cytoplasmic protein,
directs nucleolin to PRMT5 (81).

My attempts to demonstrate an effect of Syk

expression on PRMT5’s relocation either into or out of the nucleus through
immunofluorescence were unsuccessful (data not shown) as PRMT5 was evenly
distributed between the cytoplasm and nucleus and this did not appear to change as a
function of the presence or absence of Syk. However, this is not to say that under certain
stimulation conditions, such as treatment with AS1411, Syk would not have had an effect
on the localization of this complex.
It would be interesting to identify the 75 kDa substrate whose enhanced
symmetric di-methylation was Syk dependent. A reasonable method for determining this
protein’s identity would be by immunoprecipitation and mass spectrometry (89). Proteins
that were symmetrically di-methylated could be immunoprecipitated out of cell lysates
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utilizing antibodies against symmetric dimethylarginine conjugated to protein A
sepharose beads. These proteins could then be digested by endoproteinases such as
trypsin. The peptides could then be analyzed by mass spectrometry (65). Using Proteome
Discoverer provided by thermo Fisher Scientific, mass spectrometry results could be
compared against a Homo sapiens database to identify the symmetrically dimethylated
substrates, including the 75 kDa protein of interest (73).

4.3 Syk’s Interaction with SUPT5H, a Substrate of PRMT5
Previous investigations have demonstrated that PRMT5 forms complexes with
various proteins, such as CLNS1A and Sm proteins to regulate gene splicing or with
PDCD4

to

enhance

tumor

cell

growth

(45,75,90).

My

western

blot

and

immunoprecipitation assays further support this idea, as I could show that PRMT5 forms
a complex with both Syk and nucleolin. My investigation expanded upon the complex
formation between Syk and PRMT5 with my finding that PRMT5 and Syk form a
complex with SUPT5H (Figure 3.4, 3.5). Using MD-MBA-231 cells, I also demonstrated
Syk’s ability to interact with LEO1, a protein shown to be associated with SUPT5H in a
multi-protein complex that regulates class switch recombination in mature B cells (68).
My findings suggest that Syk is part of this complex, but is not required for the
SUPT5H and LEO1 interaction (Figure 3.6). Although no direct link between SUPT5H
or LEO1 expression or function in tumor development and progression has been
discovered, it is still an interesting finding as this suggests a potential new role for Syk in
later stages of B cell development. As previously mentioned, SUPT5H and LEO1 are
components of a larger complex containing the fact complex, PAF complex, SUPT4H,
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AID and SUPT6H, which regulate the ability of a mature B cell to undergo isotype
switching resulting from IgM to IgA or IgE (67,82).
Further work would be necessary to formally demonstrate a role for Syk in class
switch recombination. The Honjo group developed an in vitro class switching system in
which CH12F3, a subclone of the CH12.LX lymphoma cell, can be induced to switch
surface IgM to IgA (91). In this system, cells expressing surface IgM are treated with IL4, transforming growth factor beta (TGF-β), and CD40L for 72 hours to induce class
switching (91). Class switch recombination could then be assessed utilizing flow
cytometry by staining the surface Ig with antibodies against IgM and IgA (91,92). By
treating these cells with a Syk inhibitor, such as piceatannol or R406, one could measure
the direct effect Syk activity has on the mature B cell’s ability to undergo class switch
recombination. Given previous studies demonstrating Syk’s expression is required for B
cell development and maturation, its role in mature B cell class switch recombination
would be an interesting cellular mechanism to investigate further.

4.4 Syk Interaction with PRMT7
PRMT7 overexpression is associated with highly invasive carcinomas (57).
Moreover,

its

two

N-terminal

tyrosines

determined

in

our

Syk

dependent

phosphoproteomic mass spectrometry analysis and their unique placement within a
region of acidic residues made it a protein of interest to examine for a potential Syk
interaction (73,84). Difficulty in obtaining antibodies that were selective enough against
PRMT7 led to my use of PRMT7-GFP. I transfected the GFP tagged PRMT7 into DG75
and DG75 Syk shRNA knockdown Burkitt’s lymphoma cells, as these cells express
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endogenous Syk and are fairly easy to transfect. Although the transfection was
successful, I was unable to detect a Syk interaction, or a Syk-dependent phosphorylation
of the PRMT7-GFP (Figure 3.7). This may indicate that Syk interacts with PRMT5, but
not PRMT7. However, one cannot rule out that the possibility that the GFP tag may be
causing steric interference at the site where Syk interacts with PRMT7. The site of
tyrosine phosphorylation on PRMT7 is, in fact, located near the N-terminus of the
protein.
A reasonable alternative to transiently transfecting cells with PRMT7-GFP would
be to use an in vitro protein kinase assay to confirm the ability of Syk to phosphorylate
PRMT7. Utilizing a GST-PRMT7 bacterial expressing plasmid that can be obtained
from Addgene and His6-Syk, I could express and ability to purify these proteins from
bacteria and HEK293T cells, respectively. Both GST-PRMT7 and His6--Syk could then
be incubated together with the addition of [γ-32P]ATP. Phosphorylation by Syk could be
detected by autoradiography. Given that the sites of potential Syk phosphorylation are in
the region where SAM binds, this protein kinase assay could also be useful in measuring
Syk’s effect on PRMT7’s catalytic activity. By incubating GST-PRMT7 and His6-Syk in
a buffer containing a peptide sequence that resembles a substrate of PRMT7 and
[14C]AdoMet, the methylated products could be isolated by P81 filter paper and
quantified using a scintillation counter.

4.5 Conclusions
In summary, I have shown that Syk alters symmetric dimethylation of a protein
that is roughly 75 kDa. Using breast cancer cell models, Syk was found to interact with
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PRMT5, which is the only known methyltransferase shown to catalyze the symmetric
addition of two methyl groups to an arginine residue. Interestingly, this interaction is
dependent on the presence of nucleolin. The interaction between PRMT5 and Syk
provides preliminary evidence on a mechanism by which Syk expression could alter
symmetric dimethylation. Further investigation of this mechanism, as well as the 75 kDa
protein whose methylation is altered by Syk expression, is required.
Through examination of substrates of both PRMT5 and Syk, I was able to
demonstrate Syk’s ability to form a complex with SUPT5H and LEO1 proteins. These
preliminary findings suggest a new, additional role that Syk plays in B cell development
and differentiation following activation.
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